

IMPACT OF LONG-ACTING OCTREOTIDE ON THE QUALITY OF LIFE OF PATIENTS WITH BLEEDING FROM INTESTINAL ANGIODYSPLASIAS



A. IRAOLAGOITIA FRAILE, N. GOMEZ ECHEVARRIA, H. FILARDO LOPEZ, F. NAVARRO HERNANDEZ, M. ELOLA PLAZAOLA, A. GONZALEZ MENA
Hospital Universitario Basurto, Bilbao, Biscay, Spain. Correspondence to: amaia.iraolagoitiafraile@osakidetza.eus

BACKGROUND AND IMPORTANCE

Analysis of the **efficacy and safety** of long-acting octreotide (Octreotido-LAR) in patients with recurrent bleeding from intestinal angiodysplasias and its impact on **quality of life**.

AIM AND OBJECTIVES

Retrospective study of patients treated with Octreotide-LAR from **2021 to 2024**.




MATERIAL AND METHODS

✓ All patients who had received at least 12 monthly administrations of the drug were included.




- No. endoscopic procedures
- No. blood transfusions
- No. iron therapy
- No. hospital admissions
- Mean baseline Hb level

RESULTS



Dose:
20mg/ month im. (N=15)
10mg/month im. (N=2)

YEAR BEFORE TREATMENT				
Hb (g/dl)	Fe iv	Blood trans.	Admissions	Endoscopic trt.
9,9	6	13	2	1
10,5	4	6	3	2
10,3	2	13	4	3
9,5	4	8	1	0
9,8	7	13	2	1
11,3	1	12	3	0
9,8	4	14	1	1
9,4	1	7	2	2
8,9	1	2	1	1
9,8	0	7	3	2
9,3	11	7	1	0
8,8	6	8	3	1
8,6	2	2	1	1
9,1	3	5	3	4
7,4	5	16	3	1
10,4	6	9	5	3
7,8	2	20	2	5
9,4	65	162	40	28



YEAR AFTER TREATMENT				
Hb (g/dl)	Fe iv	Blood trans.	Admissions	Endoscopic trt.
8,4	1	4	1	1
9,2	1	0	0	0
13,1	3	4	3	0
12,2	1	0	0	0
8,6	3	5	0	0
12,8	0	0	1	0
10,5	3	14	2	0
9,8	1	2	1	1
14,3	2	0	2	1
13,3	4	0	0	0
8,4	6	2	0	0
11,9	1	2	2	1
10,1	2	12	1	0
10,3	1	2	4	0
9,2	3	16	4	2
13,6	1	0	1	2
11,9	2	8	1	0
10,9	35	71	23	8

CONCLUSION AND RELEVANCE

In our cohort, Octreotide-LAR at a dose of 20 mg/month was **safe and effective** in reducing transfusion requirements, hospital admissions, and endoscopic treatments, which translated into an **improvement in patients' quality of life**.

